Metformin-associated lactic acidosis: Current perspectives on causes and risk (Q26771648)

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Frequency of inappropriate metformin prescriptions

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Kidney function and age are both predictors of pharmacokinetics of metformin.

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Blood lactate and pyruvate levels in diabetic patients treated with biguanides with and without sulphonylureas

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Metformin and the intestine

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Contraindications to metformin therapy among patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Impact of Japanese regulatory action on metformin-associated lactic acidosis in type II diabetes patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Acute renal failure and metformin-associated lactic acidosis following colonoscopy

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Adverse event notifications implicating metformin with lactic acidosis in Australia

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Metformin overdose with a resultant serum pH of 6.59: survival without sequalae

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Occult metformin toxicity in three patients with profound lactic acidosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

An overview of metformin in the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Effects of metformin on the pathways of glucose utilization after oral glucose in non-insulin-dependent diabetes mellitus patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

1 reference

7 January 2021

Successful treatment of severe lactic acidosis caused by a suicide attempt with a metformin overdose

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Metformin in chronic kidney disease: more harm than help?

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Plasma biguanide levels are correlated with metabolic effects in diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Metformin--mode of action and clinical implications for diabetes and cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Chronic kidney disease: Metformin increases risk of mortality in patients with advanced chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

The influence of renal function on lactate and glucose metabolism

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

The relationship between metformin therapy and the fasting plasma lactate in type 2 diabetes: The Fremantle Diabetes Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Metformin and lactic acidosis: cause or coincidence? A review of case reports

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Lactic acidosis in metformin therapy: searching for a link with metformin in reports of 'metformin-associated lactic acidosis'.

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Metformin-associated lactic acidosis: a rare or very rare clinical entity?

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Contraindications to metformin therapy in patients with Type 2 diabetes--a population-based study of adherence to prescribing guidelines

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Metabolic effects of metformin in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

1 reference

7 January 2021

Lactic acidosis in patients with diabetes treated with metformin

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Case records of the Massachusetts General Hospital. Case 23-2013. A 54-year-old woman with abdominal pain, vomiting, and confusion.

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I.

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Metformin-induced lactic acidosis with emphasis on the anion gap.

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

High anion gap metabolic acidosis in suicide: don't forget metformin intoxication--two patients' experiences

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Helicobacter pylori infection decreases metformin tolerance in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Severe lactic acidosis and rhabdomyolysis following metformin and ramipril overdose.

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Bicarbonate haemodialysis as a treatment of metformin overdose

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Combination of intermittent haemodialysis and high-volume continuous haemofiltration for the treatment of severe metformin-induced lactic acidosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Metformin-associated lactic acidosis in type 2 diabetes mellitus: incidence and presentation in common clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Severe lactic acidosis complicating metformin overdose successfully treated with high-volume venovenous hemofiltration and aggressive alkalinization

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Metformin-associated lactic acidosis: a prognostic and therapeutic study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

The MALAdy of metformin poisoning: Is CVVH the cure?

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

A justification for less restrictive guidelines on the use of metformin in stable chronic renal failure.

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Comment on 'A justification for less restrictive guidelines on the use of metformin in stable chronic renal failure'

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Cardiovascular, metabolic and hormonal responses to the progressive exercise performed to exhaustion in patients with type 2 diabetes treated with metformin or glyburide

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Fulminant lactic acidosis in two patients with Type 2 diabetes treated with metformin

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Severe lactic acidosis treated with prolonged hemodialysis: recovery after massive overdoses of metformin

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Pharmacist review prevents evolving metformin-associated lactic acidosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Metformin associated lactic acidosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Interpreting the consequences of metformin accumulation in an emergency context: impact of the time frame on the blood metformin levels.

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Mitochondrial respiratory complex I regulates neutrophil activation and severity of lung injury

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Lactic acidosis: from sour milk to septic shock

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Metformin-induced lactic acidosis: a case series

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Lactic acidosis secondary to metformin overdose: a case report

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Metformin-associated lactic acidosis presenting as an ischemic gut in a patient who then survived a cardiac arrest: a case report

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Metformin-associated lactic acidosis and temporary ileostomy: a case report

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Metformin: an old but still the best treatment for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

The prognostic value of blood pH and lactate and metformin concentrations in severe metformin-associated lactic acidosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Bench-to-bedside review: lactate and the kidney

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Metformin-associated lactic acidosis in an intensive care unit.

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Oxygen consumption is depressed in patients with lactic acidosis due to biguanide intoxication

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Outcome of severe lactic acidosis associated with metformin accumulation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Metformin-induced lactic acidosis: no one left behind

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Management of metformin-associated lactic acidosis by continuous renal replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Clinical Pharmacokinetics of Metformin

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: clinical recommendations

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Effect of gastric bypass surgery on the absorption and bioavailability of metformin.

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Metformin and exercise in type 2 diabetes: examining treatment modality interactions

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Use of metformin in the setting of mild-to-moderate renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Risk of Lactic Acidosis or Elevated Lactate Concentrations in Metformin Users With Renal Impairment: A Population-Based Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Incidence of lactic acidosis in patients with type 2 diabetes with and without renal impairment treated with metformin: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions?

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

1 reference

7 January 2021

Role of metformin accumulation in metformin-associated lactic acidosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Incidence of lactic acidosis in metformin users

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

The phantom of lactic acidosis due to metformin in patients with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Metformin overdose-induced hypoglycemia in the absence of other antidiabetic drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Metformin-associated lactic acidosis: predisposing factors and outcome

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Metformin in patients with chronic kidney disease: strengths and weaknesses

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Monitoring of metformin-induced lactic acidosis in a diabetic patient with acute kidney failure and effect of hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021

Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate

1 reference

https://api.crossref.org/works/10.1016%2FJ.METABOL.2015.10.014

7 January 2021